Equities analysts expect that Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) will announce earnings per share (EPS) of $3.82 for the current quarter, Zacks reports. Seven analysts have issued estimates for Regeneron Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at $3.23 and the highest estimate coming in at $4.57. Regeneron Pharmaceuticals reported earnings per share of $3.13 in the same quarter last year, which would suggest a positive year-over-year growth rate of 22%. The business is expected to issue its next earnings report on Friday, November 3rd.

On average, analysts expect that Regeneron Pharmaceuticals will report full year earnings of $14.79 per share for the current fiscal year, with EPS estimates ranging from $12.41 to $17.07. For the next year, analysts forecast that the company will post earnings of $16.37 per share, with EPS estimates ranging from $13.35 to $18.30. Zacks’ EPS averages are an average based on a survey of analysts that cover Regeneron Pharmaceuticals.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported $4.17 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.67 by $1.50. Regeneron Pharmaceuticals had a return on equity of 25.58% and a net margin of 22.05%. The business had revenue of $1.47 billion for the quarter, compared to analysts’ expectations of $1.36 billion. During the same period in the previous year, the business posted $2.82 EPS. The firm’s quarterly revenue was up 21.2% compared to the same quarter last year.

Several research analysts have recently commented on the company. UBS AG set a $489.00 price objective on Regeneron Pharmaceuticals and gave the stock a “buy” rating in a research note on Friday, May 5th. BMO Capital Markets raised their price objective on Regeneron Pharmaceuticals from $412.00 to $421.00 and gave the stock a “hold” rating in a research note on Monday, May 15th. Piper Jaffray Companies raised their price objective on Regeneron Pharmaceuticals from $446.00 to $557.00 and gave the stock an “overweight” rating in a research note on Tuesday, June 20th. Goldman Sachs Group, Inc. (The) reaffirmed a “neutral” rating and issued a $472.00 price objective (up previously from $469.00) on shares of Regeneron Pharmaceuticals in a research note on Wednesday, August 9th. Finally, Jefferies Group LLC reaffirmed a “hold” rating and issued a $471.00 price objective (up previously from $418.00) on shares of Regeneron Pharmaceuticals in a research note on Wednesday, August 9th. Two investment analysts have rated the stock with a sell rating, thirteen have issued a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the stock. The stock presently has an average rating of “Hold” and an average target price of $495.59.

Shares of Regeneron Pharmaceuticals (NASDAQ REGN) opened at 467.98 on Friday. The company has a market capitalization of $49.62 billion, a PE ratio of 46.95 and a beta of 1.66. The stock’s 50 day moving average price is $489.51 and its 200 day moving average price is $430.92. Regeneron Pharmaceuticals has a 12 month low of $325.35 and a 12 month high of $543.55.

In related news, Chairman P Roy Vagelos sold 15,191 shares of the business’s stock in a transaction on Friday, August 18th. The stock was sold at an average price of $470.15, for a total transaction of $7,142,048.65. Following the completion of the transaction, the chairman now owns 329,543 shares in the company, valued at approximately $154,934,641.45. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, SVP Michael S. Aberman sold 2,269 shares of the business’s stock in a transaction on Thursday, June 22nd. The shares were sold at an average price of $532.42, for a total value of $1,208,060.98. Following the transaction, the senior vice president now owns 9,193 shares of the company’s stock, valued at approximately $4,894,537.06. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 84,404 shares of company stock valued at $40,303,792. 10.40% of the stock is owned by company insiders.

Institutional investors have recently bought and sold shares of the stock. Korea Investment CORP boosted its position in Regeneron Pharmaceuticals by 223.9% in the first quarter. Korea Investment CORP now owns 298 shares of the biopharmaceutical company’s stock worth $115,000 after buying an additional 206 shares during the last quarter. Fieldpoint Private Securities LLC acquired a new position in Regeneron Pharmaceuticals during the second quarter worth about $130,000. Sterling Investment Advisors Ltd. boosted its position in Regeneron Pharmaceuticals by 11.2% in the second quarter. Sterling Investment Advisors Ltd. now owns 278 shares of the biopharmaceutical company’s stock worth $137,000 after buying an additional 28 shares during the last quarter. FNY Managed Accounts LLC acquired a new position in Regeneron Pharmaceuticals during the first quarter worth about $140,000. Finally, FNY Partners Fund LP boosted its position in Regeneron Pharmaceuticals by 200.0% in the second quarter. FNY Partners Fund LP now owns 300 shares of the biopharmaceutical company’s stock worth $147,000 after buying an additional 200 shares during the last quarter. Institutional investors own 67.16% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Brokerages Anticipate Regeneron Pharmaceuticals, Inc. (REGN) to Announce $3.82 EPS” was first reported by American Banking News and is the sole property of of American Banking News. If you are viewing this piece on another domain, it was copied illegally and reposted in violation of international copyright & trademark laws. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2017/08/20/brokerages-anticipate-regeneron-pharmaceuticals-inc-regn-to-announce-3-82-eps.html.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Get a free copy of the Zacks research report on Regeneron Pharmaceuticals (REGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.